Aveanna Healthcare (NASDAQ:AVAH) Given New $10.00 Price Target at Royal Bank Of Canada

Aveanna Healthcare (NASDAQ:AVAH) had its price target raised by Royal Bank Of Canada from $9.00 to $10.00 in a research note published on Friday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

A number of other research firms have also issued reports on AVAH. Truist Financial lowered their price target on Aveanna Healthcare from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Monday, April 13th. UBS Group raised their price target on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. Raymond James Financial raised Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a report on Friday, March 20th. Weiss Ratings lowered Aveanna Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Barclays lowered their price target on Aveanna Healthcare from $11.00 to $9.50 and set an “overweight” rating on the stock in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.44.

Aveanna Healthcare Stock Performance

Shares of AVAH stock opened at $7.72 on Friday. The stock’s 50-day moving average is $6.71 and its two-hundred day moving average is $7.92. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of 6.54 and a beta of 1.93. Aveanna Healthcare has a 1 year low of $3.73 and a 1 year high of $10.32. The company has a debt-to-equity ratio of 6.62, a quick ratio of 1.32 and a current ratio of 1.32.

Aveanna Healthcare (NASDAQ:AVAH) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.05. Aveanna Healthcare had a return on equity of 210.63% and a net margin of 10.37%.The firm had revenue of $647.92 million for the quarter, compared to analyst estimates of $613.22 million. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Analysts predict that Aveanna Healthcare will post 0.56 earnings per share for the current year.

Insider Buying and Selling

In other Aveanna Healthcare news, CEO Jeff Shaner sold 173,225 shares of Aveanna Healthcare stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $1,248,952.25. Following the sale, the chief executive officer owned 2,650,892 shares of the company’s stock, valued at approximately $19,112,931.32. The trade was a 6.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Matthew Buckhalter sold 13,512 shares of Aveanna Healthcare stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $97,421.52. Following the completion of the sale, the chief financial officer directly owned 529,243 shares in the company, valued at $3,815,842.03. This represents a 2.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 738,957 shares of company stock worth $5,458,175 in the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Aveanna Healthcare

A number of institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd boosted its holdings in Aveanna Healthcare by 8.9% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock valued at $126,000 after purchasing an additional 1,151 shares in the last quarter. Barclays PLC boosted its holdings in Aveanna Healthcare by 0.8% in the 3rd quarter. Barclays PLC now owns 179,359 shares of the company’s stock valued at $1,591,000 after purchasing an additional 1,366 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Aveanna Healthcare by 4.5% in the 3rd quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock valued at $316,000 after purchasing an additional 1,528 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Aveanna Healthcare by 9.8% during the 4th quarter. Intech Investment Management LLC now owns 19,483 shares of the company’s stock worth $159,000 after acquiring an additional 1,739 shares in the last quarter. Finally, Balboa Wealth Partners boosted its stake in shares of Aveanna Healthcare by 13.5% during the 4th quarter. Balboa Wealth Partners now owns 16,890 shares of the company’s stock worth $138,000 after acquiring an additional 2,007 shares in the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Key Stories Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Aveanna reported Q1 2026 EPS of $0.18, topping the $0.13 consensus estimate, while revenue came in at $647.9 million versus expectations of $613.2 million. Article Title
• Positive Sentiment: The company raised 2026 revenue guidance to $2.56 billion-$2.58 billion and adjusted EBITDA guidance to $328 million-$332 million, signaling management sees continued momentum ahead. Article Title
• Positive Sentiment: Stephens upgraded AVAH from “equal weight” to “overweight” and increased its price target to $11, reflecting improved confidence in the stock’s outlook. Article Title
• Positive Sentiment: Royal Bank of Canada also raised its price target on AVAH to $10 from $9, adding to the generally favorable analyst response after earnings. Article Title
• Neutral Sentiment: Recent earnings-call transcripts and recap articles largely repeated the same message: strong quarterly results, revenue growth, and improved guidance, reinforcing the bullish narrative but not adding new catalysts. Article Title

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.